Necrotizing Hemorrhagic Gastritis following Acute Myeloid Leukemia Induction with Midostaurin: An Unexpected Complication

被引：4

作者：

Shimony, Shai ^{[1
,2
]}

Mintz, Hilla Reiss ^{[3
]}

Beryozkin, Yulia Shvartser ^{[4
]}

Shoham, Avivit ^{[5
]}

Raanani, Pia ^{[1
,2
]}

Wolach, Ofir ^{[1
,2
]}

机构：

[1] Beilinson Med Ctr, Davidoff Canc Ctr, Inst Hematol, Rabin Med Ctr, Petah Tiqwa, Israel

[2] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel

[3] Beilinson Med Ctr, Div Gastroenterol, Rabin Med Ctr, Petah Tiqwa, Israel

[4] Beilinson Med Ctr, Div Pathol, Rabin Med Ctr, Petah Tiqwa, Israel

[5] Beilinson Med Ctr, Radiol Dept, Rabin Med Ctr, Petah Tiqwa, Israel

来源：

ACTA HAEMATOLOGICA | 2020年 / 143卷 / 01期

关键词：

Acute myeloid leukemia; Midostaurin; Hemorrhagic gastritis;

D O I：

10.1159/000500975

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Midostaurin is a tyrosine multikinase inhibitor approved for the treatment of patients with newly diagnosed acute myeloid leukemia (AML) with mutated Fms-like tyrosine kinase-3. We describe a case report of a 49-year-old AML patient treated with an intensive chemotherapy regimen followed by midostaurin. After achieving complete remission with blood count recovery, he suffered from a serious, rare complication of necrotizing hemorrhagic gastritis with no evidence of infection or malignant infiltration, possibly associated with midostaurin therapy.

引用

页码：65 / 68

页数：4

共 50 条

[21] Acute hemorrhagic leukoencephalitis in patients with acute myeloid leukemia in hematologic complete remission
Pagano, L
Larocca, LM
Vaccario, ML
Masullo, C
Antinori, A
Pierconti, F
Tartaglione, T
Cattani, P
Mele, L
Equitani, F
Leone, G
HAEMATOLOGICA, 1999, 84 (03) : 270 - 274
[22] Post-Induction Treatment for Acute Myeloid Leukemia: Something Change?
Jaramillo, Sonia
Schlenk, Richard F.
CURRENT ONCOLOGY REPORTS, 2021, 23 (09)
[23] Necrotizing fasciitis in a young patient with acute myeloid leukemia - A diagnostic challenge
Brumann M.
Bogner V.
Völkl A.
Sotlar K.
Euler E.
Mutschler W.
Patient Safety in Surgery, 8 (1)
[24] Gut Microbiome Signatures Are Predictive of Infectious Risk Following Induction Therapy for Acute Myeloid Leukemia
Galloway-Pena, Jessica R.
Shi, Yushu
Peterson, Christine B.
Sahasrabhojane, Pranoti
Gopalakrishnan, Vancheswaran
Brumlow, Chelcy E.
Daver, Naval G.
Alfayez, Mansour
Boddu, Prajwal C.
Khan, Md Abdul Wadud
Wargo, Jennifer A.
Do, Kim-Anh
Jenq, Robert R.
Kontoyiannis, Dimitrios P.
Shelburne, Samuel A.
CLINICAL INFECTIOUS DISEASES, 2020, 71 (01) : 63 - 71
[25] New induction and postinduction strategies in acute myeloid leukemia
Burnett, Alan K.
CURRENT OPINION IN HEMATOLOGY, 2012, 19 (02) : 76 - 81
[26] Induction of Acute Myeloid Leukemia with Idarubicin, Cytarabine and Cladribine
Wiedower, Eric
Jamy, Omer
Martin, Michael G.
ANTICANCER RESEARCH, 2015, 35 (11) : 6287 - 6290
[27] Acute myeloid leukemia induction with cladribine: Outcomes by age and leukemia risk
Schoen, Martin W.
Woelich, Susan K.
Braun, James T.
Reddy, Dhinesh V.
Fesler, Mark J.
Petruska, Paul J.
Freter, Carl E.
Lionberger, Jack M.
LEUKEMIA RESEARCH, 2018, 68 : 72 - 78
[28] Midostaurin/PKC412 for the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia
Luskin, Marlise R.
DeAngelo, Daniel J.
EXPERT REVIEW OF HEMATOLOGY, 2017, 10 (12) : 1033 - 1045
[29] Clinical and economic analysis of patients with acute myeloid leukemia by FLT3 status and midostaurin use at a Comprehensive Cancer Center
Willis, Connor
Menon, Jyothi
Unni, Sudhir
Au, Trang
Yoo, Minkyoung
Biskupiak, Joseph
Brixner, Diana
Ndife, Briana
Joseph, George
Bonifacio, Gaetano
Stein, Eytan
Tantravahi, Srinivas
Shami, Paul J.
Kovacsovics, Tibor
Stenehjem, David
LEUKEMIA RESEARCH, 2019, 87
[30] Midostaurin: A New Oral Agent Targeting FMS-Like Tyrosine Kinase 3-Mutant Acute Myeloid Leukemia
Stansfield, Lindsay C.
Pollyea, Daniel A.
PHARMACOTHERAPY, 2017, 37 (12): : 1586 - 1599

← 1 2 3 4 5 →